Details of Drug

Drug General Information (ID: D0119)
Drug Name	Atomoxetine
Drug Type	Small molecule
Drug Synonymous	Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine Click to Show/Hide
Disease Class	6A05: Attention deficit hyperactivity disorder
Therapeutic Class	Cns Stimulants/Adrenergic Uptake Inhibitors
Structure
Structure	3D Structure		2D Structure
Formula	C17H21NO
InChI	1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
InChIKey	VHGCDTVCOLNTBX-QGZVFWFLSA-N
Canonical SMILES	CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2
External Link
	Pubchem ID	54841
	CAS Number	83015-26-3
	CHEBI ID	127342
	TTD ID	D04CRN
	VARIDT ID	DR00393

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects BM010 Transporter inhibition BM017 CYP450 enzyme inhibition BM018 Non-CYP450 enzyme inhibition BM038 Additive CNS depression effects BM041 Additive hypertensive effects BM042 Additive hypotensive effects BM049 Increased risk of atrioventricular block BM055 Increased risk of hepatotoxicity BM061 Increased risk of hyperpyrexia BM069 Increased risk of lowers seizure threshold BM076 Increased risk of prolong QT interval BM081 Increased risk of ventricular arrhythmias
Relation Graph

Full list of drugs interacting with Atomoxetine
Affected cellular transport
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 34
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0338		Cinacalcet	C22H22F3N	156419	Major		Inter Info	[40], [41], [42]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Major		Inter Info	[40], [41], [42]
D0676		Fluoxetine	C17H18F3NO	3386	Major		Inter Info	[40], [41], [42]
D1229		Paroxetine	C19H20FNO3	43815	Major		Inter Info	[40], [41], [42]
D0007		Abiraterone	C24H31NO	132971	Moderate		Inter Info	[40], [226], [42]
D0220		Bupropion	C13H18ClNO	444	Moderate		Inter Info	[40], [226], [42]
D0298		Celecoxib	C17H14F3N3O2S	2662	Moderate		Inter Info	[40], [226], [42]
D0337		Cimetidine	C10H16N6S	2756	Moderate		Inter Info	[40], [226], [42]
D0356		Clobazam	C16H13ClN2O2	2789	Moderate		Inter Info	[40], [226], [42]
D0375		Cobicistat	C40H53N7O5S2	25151504	Moderate		Inter Info	[250]
D0424		Darifenacin	C28H30N2O2	444031	Moderate		Inter Info	[40], [226], [42]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[40], [226], [42]
D0457		Dexfenfluramine	C12H16F3N	66265	Moderate		Inter Info	[40], [226], [42]
D0467		Dextropropoxyphene	C22H29NO2	10100	Moderate		Inter Info	[40], [42], [252]
D0502		Diphenhydramine	C17H21NO	3100	Moderate		Inter Info	[40], [226], [42]
D0539		Duloxetine	C18H19NOS	60835	Moderate		Inter Info	[40], [226], [42]
D0559		Eliglustat	C23H36N2O4	23652731	Moderate		Inter Info	[40], [226], [42]
D0638		Fedratinib	C27H36N6O3S	16722836	Moderate		Inter Info	[40], [226], [42]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[40], [226], [42]
D0724		Givosiran	C78H139N11O30	119058042	Moderate		Inter Info	[40], [226], [42]
D0732		Glycerol phenylbutyrate	C33H38O6	10482134	Moderate		Inter Info	[40], [226], [42]
D0735		Goldenseal	NA	NA	Moderate		Inter Info	[40], [226], [42]
D0793		Imatinib	C29H31N7O	5291	Moderate		Inter Info	[40], [226], [42]
D0952		Lorcaserin	C11H14ClN	11658860	Moderate		Inter Info	[40], [226], [42]
D0960		Lumefantrine	C30H32Cl3NO	6437380	Moderate		Inter Info	[2], [3], [272]
D1074		Mirabegron	C21H24N4O2S	9865528	Moderate		Inter Info	[40], [226], [42]
D1194		Oxamniquine	C14H21N3O3	4612	Moderate		Inter Info	[40], [226], [42]
D1339		Primaquine	C15H21N3O	4908	Moderate		Inter Info	[40], [226], [42]
D1415		Ritonavir	C37H48N6O5S2	392622	Moderate		Inter Info	[40], [226], [42]
D1423		Rolapitant	C25H26F6N2O2	10311306	Moderate		Inter Info	[302]
D1505		Stiripentol	C14H18O3	5311454	Moderate		Inter Info	[40], [226], [42]
D1553		Terbinafine	C21H25N	1549008	Moderate		Inter Info	[40], [226], [42]
D1383		Ranolazine	C24H33N3O4	56959	Moderate		Inter Info	[40], [226], [42]
D1581		Ticlopidine	C14H14ClNS	5472	Moderate		Inter Info	[40], [226], [42]
	Non-CYP450 enzyme inhibition					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1437		Safinamide	C17H19FN2O2	131682	Moderate		Inter Info	[303], [100], [101], [2], [3], [304], [103], [104], [105], [305], [106], [147], [110], [306], [117], [169], [298], [307], [120]
Pharmacodynamic additive effects
	Additive CNS depression effects					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0452		Deutetrabenazine	C19H27NO3	73437646	Moderate		Inter Info	[251]
D1673		Valbenazine	C24H38N2O4	24795069	Moderate		Inter Info	[318]
	Additive hypertensive effects					Drug Num: 40
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0377		Cocaine (nasal)	C17H21NO4	446220	Major		Inter Info	[3], [47], [48]
D0378		Cocaine (topical)	C17H21NO4	446220	Major		Inter Info	[3], [47], [48]
D0600		Esketamine	C13H16ClNO	182137	Major		Inter Info	[2], [57]
D0103		Arformoterol	C19H24N2O4	3083544	Moderate		Inter Info	[113], [42], [234]
D0510		Dobutamine	C18H23NO3	36811	Moderate		Inter Info	[113], [42], [234]
D0517		Dopamine	C8H11NO2	681	Moderate		Inter Info	[113], [42], [234]
D0579		Ephedrine	C10H15NO	9294	Moderate		Inter Info	[113], [42], [234]
D0581		Epinephrine	C9H13NO3	5816	Moderate		Inter Info	[113], [42], [234]
D0857		Isometheptene	C9H19N	22297	Moderate		Inter Info	[113], [42], [234]
D0859		Isoprenaline	C11H17NO3	3779	Moderate		Inter Info	[113], [42], [234]
D0921		Levonordefrin	C9H13NO3	164739	Moderate		Inter Info	[113], [42], [234]
D0924		Levosalbutamol	C13H21NO3	123600	Moderate		Inter Info	[113], [42], [234]
D1002		Mephentermine	C11H17N	3677	Moderate		Inter Info	[113], [42], [234]
D1027		Methoxamine	C11H17NO3	6082	Moderate		Inter Info	[113], [42], [234]
D1153		Norepinephrine	C8H11NO3	439260	Moderate		Inter Info	[113], [42], [234]
D1171		Olodaterol	C21H26N2O5	11504295	Moderate		Inter Info	[113], [42], [234]
D1185		Orciprenaline	C11H17NO3	4086	Moderate		Inter Info	[113], [42], [234]
D1276		Phenylephrine	C9H13NO2	6041	Moderate		Inter Info	[113], [42], [234]
D1281		Phenylpropanolamine	C9H13NO	26934	Moderate		Inter Info	[113], [42], [234]
D1298		Pirbuterol	C12H20N2O3	4845	Moderate		Inter Info	[113], [42], [234]
D1363		Pseudoephedrine	C10H15NO	7028	Moderate		Inter Info	[113], [42], [234]
D1374		Racepinephrine	C9H13NO3	838	Moderate		Inter Info	[113], [42], [234]
D1385		Rasagiline	C12H13N	3052776	Moderate		Inter Info	[100], [143], [101], [3], [145], [102], [103], [146], [105], [106], [147], [107], [148], [149], [108], [154], [109], [155], [297], [115], [116], [118], [298], [119], [120]
D1414		Ritodrine	C17H21NO3	33572	Moderate		Inter Info	[113], [42], [234]
D1438		Salbutamol	C13H21NO3	2083	Moderate		Inter Info	[113], [42], [234]
D1440		Salmeterol	C25H37NO4	5152	Moderate		Inter Info	[113], [42], [234]
D1554		Terbutaline	C12H19NO3	5403	Moderate		Inter Info	[113], [42], [234]
D1695		Vilanterol	C24H33Cl2NO5	10184665	Moderate		Inter Info	[113], [42], [234]
D0854		Isoetharine	C13H21NO3	3762	Moderate		Inter Info	[113], [42], [234]
D1061		Midodrine	C12H18N2O4	4195	Moderate		Inter Info	[3], [319]
D0068		Amitriptyline	C20H23N	2160	Minor		Inter Info	[2], [320], [321]
D0072		Amoxapine	C17H16ClN3O	2170	Minor		Inter Info	[2], [320], [321]
D0446		Desipramine	C18H22N2	2995	Minor		Inter Info	[2], [320], [321]
D0525		Doxepin	C19H21NO	667477	Minor		Inter Info	[2], [320], [321]
D0795		Imipramine	C19H24N2	3696	Minor		Inter Info	[2], [320], [321]
D0979		Maprotiline	C20H23N	4011	Minor		Inter Info	[2], [320], [321]
D1158		Nortriptyline	C19H21N	4543	Minor		Inter Info	[2], [320], [321]
D1361		Protriptyline	C19H21N	4976	Minor		Inter Info	[2], [320], [321]
D1464		Sibutramine	C17H26ClN	5210	Minor		Inter Info	[2], [320], [321]
D1689		Venlafaxine	C17H27NO2	5656	Minor		Inter Info	[2], [320], [321]
	Additive hypotensive effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0942		Lofexidine	C11H12Cl2N2O	30668	Moderate		Inter Info	[1], [2], [3], [269], [14]
	Increased risk of atrioventricular block					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0992		Mefloquine	C17H16F6N2O	4046	Moderate		Inter Info	[3], [90], [273]
	Increased risk of hepatotoxicity					Drug Num: 21
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[1], [125], [126]
D0944		Lomitapide	C39H37F6N3O2	9853053	Major		Inter Info	[127]
D1073		Mipomersen	C230H324N67O122P19S19	118984467	Major		Inter Info	[141]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[183]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[1], [125], [126]
D0114		Asparaginase Escherichia coli	NA	NA	Moderate		Inter Info	[215], [216], [217], [2], [3], [218], [219], [220], [221], [222], [223], [224], [225]
D0113		Asparaginase Erwinia chrysanthemi	NA	NA	Moderate		Inter Info	[215], [216], [217], [2], [3], [218], [219], [220], [221], [222], [223], [224], [225]
D0199		Brentuximab vedotin	NA	NA	Moderate		Inter Info	[246]
D0232		Calaspargase pegol	NA	NA	Moderate		Inter Info	[215], [216], [217], [2], [3], [218], [219], [220], [221], [222], [223], [224], [225]
D0248		Cannabidiol	C21H30O2	644019	Moderate		Inter Info	[3], [247]
D0357		Clofarabine	C10H11ClFN5O3	119182	Moderate		Inter Info	[248]
D0584		Epirubicin	C27H29NO11	41867	Moderate		Inter Info	[2], [3], [257]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[261]
D1025		Methotrexate	C20H22N8O5	126941	Moderate		Inter Info	[3], [274]
D1106		Naltrexone	C20H23NO4	5360515	Moderate		Inter Info	[276]
D1239		Peginterferon beta-1a	NA	NA	Moderate		Inter Info	[278], [279], [280], [281]
D1389		Remdesivir	C27H35N6O8P	121304016	Moderate		Inter Info	[2], [3], [299], [300], [301]
D1589		Tioguanine	C5H5N5S	2723601	Moderate		Inter Info	[315], [316]
D1615		Trabectedin	C39H43N3O11S	108150	Moderate		Inter Info	[3], [317]
D0827		Interferon beta-1b	NA	NA	Moderate		Inter Info	[278], [279], [280], [281]
D1234		Pegaspargase	C14H19NO	436058	Moderate		Inter Info	[215], [216], [217], [2], [3], [218], [219], [220], [221], [222], [223], [224], [225]
	Increased risk of hyperpyrexia					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0853		Isocarboxazid	C12H13N3O2	3759	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D0933		Linezolid	C16H20FN3O4	441401	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D1036		Methylene blue	C16H18ClN3S	6099	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[100], [143], [101], [2], [3], [144], [145], [102], [103], [146], [104], [105], [106], [147], [107], [148], [149], [150], [151], [152], [108], [153], [154], [109], [155], [156], [157], [158], [110], [111], [159], [160], [112], [113], [161], [162], [163], [114], [164], [165], [42], [166], [115], [167], [116], [117], [168], [169], [118], [119], [170], [171], [172], [120]
D1263		Phenelzine	C8H12N2	3675	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D1345		Procarbazine	C12H19N3O	4915	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D1455		Selegiline	C13H17N	26757	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
D1620		Tranylcypromine	C9H11N	19493	Major		Inter Info	[100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [42], [115], [116], [117], [118], [119], [120]
	Increased risk of prolong QT interval					Drug Num: 140
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0084		Anagrelide	C10H7Cl2N3O	135409400	Major		Inter Info	[1], [2], [3], [4]
D0066		Amiodarone	C25H29I2NO3	2157	Major		Inter Info	[1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]
D0067		Amisulpride	C17H27N3O4S	2159	Major		Inter Info	[15]
D0149		Bedaquiline	C32H31BrN2O2	5388906	Major		Inter Info	[18]
D0230		Cabozantinib	C28H24FN3O5	25102847	Major		Inter Info	[3], [19]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Major		Inter Info	[1], [2], [3], [20]
D0320		Chloroquine	C18H26ClN3	2719	Major		Inter Info	[21], [3], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39]
D0342		Cisapride	C23H29ClFN3O4	6917698	Major		Inter Info	[1], [2], [3], [43], [44], [45]
D0370		Clozapine	C18H19ClN4	135398737	Major		Inter Info	[1], [2], [3], [46], [14]
D0393		Crizotinib	C21H22Cl2FN5O	11626560	Major		Inter Info	[49]
D0514		Dolasetron	C19H20N2O3	3033818	Major		Inter Info	[1], [2], [3], [50]
D0534		Dronedarone	C31H44N2O5S	208898	Major		Inter Info	[1], [2], [3], [51]
D0535		Droperidol	C22H22FN3O2	3168	Major		Inter Info	[1], [2], [3], [52], [53], [14]
D0599		Escitalopram	C20H21FN2O	146570	Major		Inter Info	[1], [54], [2], [3], [55], [56], [14]
D0712		Gatifloxacin	C19H22FN3O4	5379	Major		Inter Info	[60], [61], [62], [1], [2], [3], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82]
D0740		Grepafloxacin	C19H22FN3O3	72474	Major		Inter Info	[61], [1], [2], [3], [83], [84], [85]
D0749		Halofantrine	C26H30Cl2F3NO	37393	Major		Inter Info	[86], [1], [2], [3], [87], [88], [89], [90], [91]
D0750		Haloperidol	C21H23ClFNO2	3559	Major		Inter Info	[1], [2], [3], [92], [93], [94], [95], [96], [97], [14]
D0787		Ibutilide	C20H36N2O3S	60753	Major		Inter Info	[1], [2], [3], [98]
D0791		Iloperidone	C24H27FN2O4	71360	Major		Inter Info	[1], [2], [3], [99], [14]
D0872		Ivosidenib	C28H22ClF3N6O3	71657455	Major		Inter Info	[123]
D0899		Lefamulin	C28H45NO5S	25185057	Major		Inter Info	[124]
D0965		Macimorelin	C26H30N6O3	9804938	Major		Inter Info	[128]
D1010		Mesoridazine	C21H26N2OS2	4078	Major		Inter Info	[1], [2], [3], [129], [14]
D1017		Methadone	C21H27NO	4095	Major		Inter Info	[1], [2], [3], [130], [131], [132], [133], [134], [135], [136], [137], [138], [139], [14]
D1063		Mifepristone	C29H35NO2	55245	Major		Inter Info	[1], [2], [3], [140]
D1190		Osimertinib	C28H33N7O2	71496458	Major		Inter Info	[142]
D1221		Panobinostat	C21H23N3O2	6918837	Major		Inter Info	[173]
D1223		Papaverine	C20H21NO4	4680	Major		Inter Info	[174], [175], [176], [177], [178], [179], [180], [181]
D1230		Pasireotide	C58H66N10O9	9941444	Major		Inter Info	[1], [2], [3], [182]
D1343		Procainamide	C13H21N3O	4913	Major		Inter Info	[1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]
D1371		Quinidine	C20H24N2O2	441074	Major		Inter Info	[1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]
D1398		Ribociclib	C23H30N8O	44631912	Major		Inter Info	[1], [2], [3], [52], [67], [184], [185], [14]
D1444		Saquinavir	C38H50N6O5	441243	Major		Inter Info	[186], [187], [1], [2], [3], [188], [189]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[3], [190]
D1498		Sotalol	C12H20N2O3S	5253	Major		Inter Info	[1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Major		Inter Info	[61], [1], [2], [3], [192], [193], [65], [67], [69], [194], [70], [71], [195], [73], [74], [75], [76], [196], [80], [85], [197]
D1574		Thioridazine	C21H26N2S2	5452	Major		Inter Info	[1], [2], [3], [198], [52], [199], [200], [201], [14]
D1612		Toremifene	C26H28ClNO	3005573	Major		Inter Info	[1], [2], [3], [202]
D1681		Vandetanib	C22H24BrFN4O2	3081361	Major		Inter Info	[1], [2], [3], [203]
D1687		Vemurafenib	C23H18ClF2N3O3S	42611257	Major		Inter Info	[1], [2], [3], [204]
D0345		Citalopram	C20H21FN2O	2771	Major		Inter Info	[1], [2], [3], [205], [206], [14], [59]
D0508		Disopyramide	C21H29N3O	3114	Major		Inter Info	[1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]
D0513		Dofetilide	C19H27N3O5S2	71329	Major		Inter Info	[1], [2], [3], [207]
D1092		Moxifloxacin	C21H24FN3O4	152946	Major		Inter Info	[60], [61], [62], [1], [2], [3], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82]
D0003		Abarelix	C72H95ClN14O14	16131215	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0037		Alimemazine	C18H22N2S	5574	Moderate		Inter Info	[67], [185], [14]
D0095		Apalutamide	C21H15F4N5O2S	24872560	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0097		Apomorphine	C17H17NO2	6005	Moderate		Inter Info	[1], [2], [3], [233], [14]
D0105		Aripiprazole	C23H27Cl2N3O2	60795	Moderate		Inter Info	[2], [3], [235], [236], [237], [238], [239], [240]
D0112		Asenapine	C17H16ClNO	3036780	Moderate		Inter Info	[1], [2], [3], [241], [14]
D0115		Astemizole	C28H31FN4O	2247	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0180		Bicalutamide	C18H14F4N2O4S	2375	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[3], [245]
D0219		Buprenorphine	C29H41NO4	644073	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0324		Chlorpromazine	C17H19ClN2S	2726	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0336		Cilostazol	C20H27N5O2	2754	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0349		Clarithromycin	C38H69NO13	84029	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0358		Clofazimine	C27H22Cl2N4	2794	Moderate		Inter Info	[249]
D0361		Clomipramine	C19H23ClN2	2801	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0429		Daunorubicin	C27H29NO10	30323	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0437		Degarelix	C82H103ClN18O16	16136245	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0528		Doxorubicin	C27H29NO11	31703	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0529		Doxorubicin (liposomal)	C27H29NO11	31703	Moderate		Inter Info	[67], [185], [14]
D0577		Entrectinib	C31H34F2N6O2	25141092	Moderate		Inter Info	[2], [3], [256]
D0578		Enzalutamide	C21H16F4N4O2S	15951529	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0594		Eribulin	C40H59NO11	11354606	Moderate		Inter Info	[1], [2], [3], [258]
D0632		Ezogabine	C16H18FN3O2	121892	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0678		Fluphenazine	C22H26F3N3OS	3372	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0682		Flutamide	C11H11F3N2O3	3397	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0694		Foscarnet	CH3O5P	3415	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0700		Fostemsavir	C25H26N7O8P	11319217	Moderate		Inter Info	[259]
D0725		Glasdegib	C21H22N6O	25166913	Moderate		Inter Info	[260]
D0738		Granisetron	C18H24N4O	5284566	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0751		Halothane	C2HBrClF3	3562	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0758		Histrelin	C66H86N18O12	25077993	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0781		Hydroxyzine	C21H27ClN2O2	3658	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0788		Idarubicin	C26H27NO9	42890	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0903		Lenvatinib	C21H19ClN4O4	9823820	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0919		Levofloxacin	C18H20FN3O4	149096	Moderate		Inter Info	[61], [1], [2], [3], [65], [66], [67], [262], [263], [70], [71], [264], [72], [265], [73], [74], [75], [76], [266], [267], [268], [80], [85]
D0937		Lisdexamfetamine	C15H25N3O	11597698	Moderate		Inter Info	[3]
D0940		Lithium carbonate	CLi2O3	11125	Moderate		Inter Info	[67], [185], [14]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0947		Loperamide	C29H33ClN2O2	3955	Moderate		Inter Info	[270], [271]
D1026		Methotrimeprazine	C19H24N2OS	72287	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1062		Midostaurin	C35H30N4O4	9829523	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1075		Mirtazapine	C17H19N3	4205	Moderate		Inter Info	[275]
D1137		Nilutamide	C12H10F3N3O4	4493	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[61], [1], [2], [3], [65], [66], [67], [262], [263], [70], [71], [264], [72], [265], [73], [74], [75], [76], [266], [267], [268], [80], [85]
D1169		Oliceridine	C22H30N2O2S	66553195	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1181		Ondansetron	C18H19N3O	4595	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1189		Osilodrostat	C13H10FN3	44139752	Moderate		Inter Info	[3], [277]
D1215		Paliperidone	C23H27FN4O3	115237	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1216		Palonosetron	C19H24N2O	6337614	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1232		Pazopanib	C21H23N7O2S	10113978	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1246		Pentamidine	C19H24N4O2	4735	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1254		Perflutren	C3F8	6432	Moderate		Inter Info	[282], [283]
D1257		Perphenazine	C21H26ClN3OS	4748	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1290		Pimavanserin	C25H34FN3O2	10071196	Moderate		Inter Info	[286]
D1302		Pitolisant	C17H26ClNO	9948102	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1342		Probucol	C31H48O2S2	4912	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1346		Prochlorperazine	C20H24ClN3S	4917	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1352		Promethazine	C17H20N2S	4927	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1353		Propafenone	C21H27NO3	4932	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1356		Propofol	C12H18O	4943	Moderate		Inter Info	[287], [288], [289], [290], [291], [292], [293], [294], [295], [296]
D1368		Quetiapine	C21H25N3O2S	5002	Moderate		Inter Info	[52], [273], [14]
D1372		Quinine	C20H24N2O2	3034034	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1404		Rilpivirine	C22H18N6	6451164	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1413		Risperidone	C23H27FN4O2	5073	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1424		Romidepsin	C24H36N4O6S2	5352062	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1432		Rucaparib	C19H18FN3O	9931954	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1461		Sertraline	C17H17Cl2N	68617	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1491		Solifenacin	C23H26N2O2	154059	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1497		Sorafenib	C21H16ClF3N4O3	216239	Moderate		Inter Info	[1], [2], [3], [308]
D1522		Sunitinib	C22H27FN4O2	5329102	Moderate		Inter Info	[1], [2], [3], [309]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1533		Tamoxifen	C26H29NO	2733526	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1542		Telavancin	C80H106Cl2N11O27P	3081362	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1544		Telithromycin	C43H65N5O10	3002190	Moderate		Inter Info	[1], [2], [3], [310], [311], [312]
D1555		Terfenadine	C32H41NO2	5405	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1560		Tetrabenazine	C19H27NO3	6018	Moderate		Inter Info	[1], [2], [3], [313], [14]
D1596		Tizanidine	C9H8ClN5S	5487	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1634		Triclabendazole	C14H9Cl3N2OS	50248	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1637		Trifluoperazine	C21H24F3N3S	5566	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1638		Triflupromazine	C18H19F3N2S	5568	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1651		Triptorelin	C64H82N18O13	25074470	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D1682		Vardenafil	C23H32N6O4S	135400189	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1706		Voriconazole	C16H14F3N5O	71616	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0597		Erythromycin	C37H67NO13	12560	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0667		Fluconazole	C13H12F2N6O	3365	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D0737		Goserelin	C59H84N18O14	5311128	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D0908		Leuprolide	C59H84N16O12	657181	Moderate		Inter Info	[3], [208], [209], [210], [211], [212], [213], [214]
D1616		Tramadol	C16H25NO2	33741	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1683		Vasopressin	C46H65N15O12S2	644077	Moderate		Inter Info	[1], [2], [3], [52], [67], [185], [14]
D1051		Metronidazole	C6H9N3O3	4173	Minor		Inter Info	[2], [322], [323], [324]
D1516		Sulfamethoxazole	C10H11N3O3S	5329	Minor		Inter Info	[1], [2], [3], [325], [326], [327], [328]
	Increased risk of ventricular arrhythmias					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0107		Arsenic trioxide	As2O3	14888	Major		Inter Info	[16], [17]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[1], [2], [3], [58], [59]
D0868		Ivabradine	C27H36N2O5	132999	Major		Inter Info	[3], [121], [122]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[2], [191]
D0025		Adenosine	C10H13N5O4	60961	Moderate		Inter Info	[1], [227], [2], [3], [228], [229], [230], [43], [231], [232]
D0184		Bisacodyl	C22H19NO4	2391	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0269		Castor oil	C57H104O9	14030006	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0516		Donepezil	C24H29NO3	3152	Moderate		Inter Info	[1], [2], [3], [253], [254], [255]
D0701		Frangula purshiana bark	NA	NA	Moderate		Inter Info	[2], [3], [244]
D0707		Galantamine	C17H21NO3	9651	Moderate		Inter Info	[1], [2], [3], [253], [254], [255]
D0731		Glycerin	C3H8O3	753	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0887		Lactitol	C12H24O11	157355	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0888		Lactulose	C12H22O11	11333	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0970		Magnesium citrate	C12H10Mg3O14	6099959	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D0973		Magnesium hydroxide	H2MgO2	14791	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D1069		Mineral oil	NA	NA	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D1266		Phenolphthalein	C20H14O4	4764	Moderate		Inter Info	[1], [2], [3], [242], [243], [244]
D1287		Picosulfuric acid	C18H15NO8S2	5243	Moderate		Inter Info	[1], [284], [285]
D1308		Polyethylene glycol (3350 with electrolytes)	C2H6O2	174	Moderate		Inter Info	[1], [284], [285]
D1309		Polyethylene glycol (3350)	C2H6O2	174	Moderate		Inter Info	[2], [3], [244]
D1418		Rivastigmine	C14H22N2O2	77991	Moderate		Inter Info	[1], [2], [3], [253], [254], [255]
D1488		Sodium sulfate	Na2O4S	24436	Moderate		Inter Info	[1], [284], [285]
D1569		Thalidomide	C13H10N2O4	5426	Moderate		Inter Info	[2], [3], [314]

References
1	Canadian Pharmacists Association.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
5	Maxa JL, Hebeler RF, Adeeko MA "Torsades de pointes following concurrent amiodarone and levofloxacin therapy." Proc (Bayl Univ Med Cent) 19 (2006): 345-6. [PMID: 17106497]
6	Product Information. Betapace (sotalol). Berlex, Richmond, CA.
7	Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.
8	Product Information. Norpace (disopyramide). Searle, Skokie, IL.
9	Product Information. Procan SR (procainamide). Parke-Davis, Morris Plains, NJ.
10	Product Information. Quiniglute (quinidine). Berlex, Richmond, CA.
11	Product Information. Vascor (bepridil). McNeil Pharmaceutical, Raritan, NJ.
12	Trujillo TC, Nolan PE "Antiarrhythmic agents - Drug interactions of clinical significance." Drug Safety 23 (2000): 509-32. [PMID: 11144659]
13	Yamreudeewong W, DeBisschop M, Martin L, Lower D "Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs." Drug Saf 26 (2003): 421-38. [PMID: 12688833]
14	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
15	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
16	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
17	Product Information. Trisenox (arsenic trioxide) Cephalon Inc, West Chester, PA.
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
20	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
21	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
22	Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C "COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print. [PMID: 32350872]
23	National Institutes of Health (NIH) "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.".
24	Product Information. Chloroquine Phosphate (chloroquine). West-Ward Pharmaceutical Corporation, Eatontown, NJ.
25	Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
26	Product Information. Plaquenil (R). (hydroxychloroquine). Sanofi Winthrop Pharmaceuticals, New York, NY.
27	Roden DM, Harrington RA, Poppas A, Russo AM "Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment." Heart Rhythm Apr 14 (2020): epub ahead of print. [PMID: 32302703]
28	Sacher F, Fauchier L, Boveda S, et.al "Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection." Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print. [PMID: 32354666]
29	Saleh M, Gabriels J, ChangD, et.al "The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection." Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print. [PMID: 32347743]
30	Sapp JL, Alqarawi W, MacIntyre CJ, et.al "Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society." Can J Cardiol Apr 8 (2020): epub ahead of print. [PMID: 32299753]
31	Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ "Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties." Clin Pharmacokinet Ar 18 (2020): epub ahead of print. [PMID: 32306288]
32	Bessiere F, Roccia H, Deliniere A, et.al "Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit." JAMA Cardiol May 1 (2020): epub ahead of print. [PMID: 32936266]
33	Borba MGS, Val FFA, Sampaio VS, et.al "Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial." JAMA Netw Open Apr 1 (2020): epub ahead of print. [PMID: 32330277]
34	Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ "Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)" Mayo Clin Proc Apr 7 (2020): epub ahead of print. [PMID: 32359771]
35	Kapoor A, Pandurangi U, Arora V, et.al "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society." Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print. [PMID: 32278018]
36	Mercuro NJ, Yen CF, Shim DJ, et.al "Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)" JAMA Cardiol May 1:e201834 (2020): epub ahead of print. [PMID: 32936252]
37	mitra RL, Greenstein SA, Epstein lm "An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin Possible benefits of intravenous lidocaine." HeartRythm Case Rep Apr 1 (2020): epub ahead of print. [PMID: 32363145]
38	US Food and Drug Administration "FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653" ([2020, Apr 27]):.
39	US Food and Drug Administration "Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems.".
40	Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
41	Product Information. Paxil (paroxetine). GlaxoSmithKline, Research Triangle Park, NC.
42	Product Information. Strattera (atomoxetine). Lilly, Eli and Company, Indianapolis, IN.
43	Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75. [PMID: 10926350]
44	Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
45	Trinkle R "Comment: syncopal episodes associated with cisapride." Ann Pharmacother 33 (1999): 251. [PMID: 10084425]
46	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
47	Thevasagyam M, Jindal M, Allsop P, Oates J "Does epinephrine infiltration in septoplasty make any difference?" Eur Arch Otorhinolaryngol 264 (2007): 1175-8.[PMID: 17530270]
48	Product Information. Cocaine Hydrochloride (cocaine topical). Mallinckrodt Medical Inc, St. Louis, MO.
49	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50	Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.
51	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
52	Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
53	Product Information. Inapsine (droperidol). Janssen Pharmaceutica, Titusville, NJ.
54	Castro VM, Clements CC, Murphy SN, et al. "QT interval and antidepressant use: a cross sectional study of electronic health records." BMJ 346 (2013): f288. [PMID: 23360890]
55	Do A, Noohi S, Elie D, et al. Health Canada Warning on Citalopram and Escitalopram--Its Effects on Prescribing in Consultation-Liaison Psychiatry.?Psychosomatics. 2016;57(1):57-63. [PMID: 26633294]
56	Product Information. Lexapro (escitalopram). Forest Pharmaceuticals, St. Louis, MO.
57	Product Information. Spravato (esketamine). Janssen Pharmaceuticals, Titusville, NJ.
58	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
59	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".
60	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
61	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
62	Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3. [PMID: 11830802]
63	Dale KM, Lertsburapa K, Kluger J, White CM "Moxifloxacin and torsade de pointes." Ann Pharmacother 41 (2007): 336-40. [PMID: 17284508]
64	Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66. [PMID: 11180026]
65	Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9. [PMID: 17241772]
66	Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72. [PMID: 11765299]
67	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
68	Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2. [PMID: 11253862]
69	Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7. [PMID: 11141163]
70	Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6. [PMID: 11125032]
71	Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20. [PMID: 14675020]
72	Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303. [PMID: 12709719]
73	Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64. [PMID: 11858629]
74	Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124. [PMID: 15139788]
75	Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19. [PMID: 11253855]
76	Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8 discussion 668-72. [PMID: 12013370]
77	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
78	Product Information. Tequin (gatifloxacin) Bristol-Myers Squibb, Princeton, NJ.
79	Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23. [PMID: 11141146]
80	Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77. [PMID: 12052667]
81	Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF "Effects of three fluoroquinolones on QT analysis after standard treatment courses." Ann Noninvasive Electrocardiol 11 (2006): 52-6. [PMID: 16472283]
82	White CM, Grant EM, Quintiliani R "Moxifloxacin does increase the corrected QT interval." Clin Infect Dis 33 (2001): 1441-2. [PMID: 11565091]
83	Lode H, Vogel F, Elies W "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther 21 (1999): 61-74. [PMID: 10090425]
84	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
85	Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81. [PMID: 8838432]
86	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
87	Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73. [PMID: 11432537]
88	Nosten F, ter Kuile FO, Luxemburger C, et al "Cardiac effects of antimalarial treatment with halofantrine." Lancet 341 (1993): 1054-6. [PMID: 8096959]
89	Product Information. Halfan (halofantrine). GlaxoSmithKline, Philadelphia, PA.
90	Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
91	Sudden death in a traveler following halofantrine administration--Togo, 2000. MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179. [PMID: 11393488]
92	Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001): 257-61. [PMID: 11386487]
93	Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988): 568-9. [PMID: 2900948]
94	Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993): 128-32. [PMID: 8463445]
95	O'Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999): 1046-9. [PMID: 10534216]
96	Product Information. Haldol (haloperidol). McNeil Pharmaceutical, Raritan, NJ.
97	Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993): 391-4. [PMID: 8338292]
98	Product Information. Corvert (ibutilide). Pharmacia and Upjohn, Kalamazoo, MI.
99	Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
100	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
101	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
102	FISCHER E, ORLANDO J, LUDMER RL. INFLUENCIA DE METILANFETAMINA, IPRONIACIDA Y TRANILCIPROMINA SOBRE LA DEPRESI'ON PSICOMOTORA ADRENAL'INICA [EFFECT OF METHYLAMPHETAMINE, IPRONIAZID AND TRANYLCYPROMINE ON ADRENALINE PSYCHOMOTOR DEPRESSION]. Prensa Med Argent. 1964;51:1538-1540. [PMID: 14272082]
103	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
104	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
105	Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8. [PMID: 6020852]
106	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
107	Harrison WM, McGrath PJ, Stewart JW, Quitkin F "MAOIs and hypertensive crises: the role of OTC drugs." J Clin Psychiatry 50 (1989): 64-5. [PMID: 2464583]
108	Krisko I, Lewis E, Johnson JE "Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity." Ann Intern Med 70 (1969): 559-64. [PMID: 5775035]
109	Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72. [PMID: 11707061]
110	Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7. [PMID: 5655478]
111	Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
112	Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
113	Product Information. Focalin (dexmethylphenidate). Mikart Inc, Atlanta, GA.
114	Product Information. Ritalin (methylphenidate). Novartis Pharmaceuticals, East Hanover, NJ.
115	Product Information. Vyvanse (lisdexamfetamine). Shire US Inc, Florence, KY.
116	Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M "Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs." Ann N Y Acad Sci 107 (1963): 1005-15. [PMID: 13991689]
117	Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36. [PMID: 2510962]
118	Sjoqvist F "Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances." Proc R Soc Med 58 (1965): 967-78. [PMID: 4952963]
119	Smookler S, Bermudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant." Ann Intern Med 11 (1982): 482-4. [PMID: 7114595]
120	Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5. [PMID: 74715]
121	Mittal SR "Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine." J Assoc Physicians India 62 (2014): 426-7. [PMID: 25438492]
122	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.
123	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
124	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
125	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
126	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
127	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
128	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
129	Product Information. Serentil (mesoridazine) Boehringer-Ingelheim, Ridgefield, CT.
130	De Bels D, Staroukine M, Devriendt J "Torsades de pointes due to methadone." Ann Intern Med 139 (2003): E156. [PMID: 12859181]
131	Ehret GB, Desmeules JA, Broers B "Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology." Expert Opin Drug Saf 6 (2007): 289-303. [PMID: 17480178]
132	Gil M, Sala M, Anguera I, et al. "QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone." Am J Cardiol 92 (2003): 995-7. [PMID: 14556883]
133	Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS "Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes." Pharmacotherapy 23 (2003): 802-5. [PMID: 12820821]
134	Krantz MJ, Lewkowiez L, Hays H, et al "Torsade de pointes associated with very-high-dose methadone." Ann Intern Med 137 (2002): 501-4. [PMID: 12230351]
135	Krantz MJ, Mehler PS "Synthetic opioids and QT prolongation." Arch Intern Med 163 (2003): 1615 author reply 1615. [PMID: 12860589]
136	Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN "Impact of methadone treatment on cardiac repolarization and conduction in opioid users." Am J Cardiol 95 (2005): 915-8. [PMID: 15781034]
137	Mokwe EO, Ositadinma O "Torsade de pointes due to methadone." Ann Intern Med 139 (2003): W64. [PMID: 12966000]
138	Sala M, Anguera I, Cervantes M "Torsade de pointes due to methadone." Ann Intern Med 139 (2003): W64. [PMID: 12966001]
139	Walker PW, Klein D, Kasza L "High dose methadone and ventricular arrhythmias: a report of three cases." Pain 103 (2003): 321-4. [PMID: 12791438]
140	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
141	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
142	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
143	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
144	Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol 108 (1990): 1264-7. [PMID: 2205182]
145	Cuthbert MF, Greenberg MP, Morley SW "Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors." Br Med J 1 (1969): 404-6. [PMID: 5763957]
146	Davies B, Bannister R, Sever P "Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards." Lancet 1 (1978): 172-5. [PMID: 74603]
147	Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7. [PMID: 1359489]
148	Horler AR, Wynne NA "Hypertensive crisis due to pargyline and metaraminol." Br Med J 5459 (1965): 460-1. [PMID: 14314914]
149	Humberstone PM "Hypertension from cold remedies." Br Med J 1 (1969): 846. [PMID: 5813090]
150	Hunter KR, Boakes AJ, Laurence DR, Stern GM "Monoamine oxidase inhibitors and L-dopa." Br Med J 3 (1970): 388. [PMID: 5451592]
151	King MH, Richards DW "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol 110 (1990): 308-9. [PMID: 2204271]
152	Kraft KE, Dore FH "Computerized drug interaction programs: how reliable?." JAMA 275 (1996): 1087. [PMID: 8601924]
153	Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10. [PMID: 6630590]
154	Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8. [PMID: 7889639]
155	Mason AM, Buckle RM ""Cold" cures and monoamine-oxidase inhibitors." Br Med J 1 (1969): 845-6. [PMID: 5813089]
156	Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol 113 (1995): 77-83. [PMID: 7826297]
157	Paykel ES "Hallucinosis on combined methyldopa and pargyline." Br Med J 1 (1966): 803. [PMID: 5910115]
158	Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4. [PMID: 16189050]
159	Product Information. Aldomet (methyldopa). Merck & Co, Inc, West Point, PA.
160	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
161	Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
162	Product Information. Mirvaso (brimonidine topical). Galderma Laboratories Inc, Cranbury, NJ.
163	Product Information. Parcopa (carbidopa-levodopa). Schwarz Pharma, Mequon, WI.
164	Product Information. Sinemet (carbidopa-levodopa). DuPont Pharmaceuticals, Wilmington, DE.
165	Product Information. Stalevo 50 (carbidopa/entacapone/levodopa). Novartis Pharmaceuticals, East Hanover, NJ.
166	Product Information. Tyzine (tetrahydrozoline). Kenwood Laboratories, Fairfield, NJ.
167	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
168	Sharpe J, Marquez-Julio A, Ashby P "Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report." Can Med Assoc J 107 (1972): 296-300. [PMID: 5056115]
169	Sjoerdsma A "Catecholamine-drug interactions in man." Pharmacol Rev 18 (1966): 673-83. [PMID: 5904180]
170	Teychenne PF, Calne DB, Lewis PJ, Findley LJ "Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase." Clin Pharmacol Ther 18 (1975): 273-7. [PMID: 1164817]
171	van Rossum JM "Potential danger of monoamineoxidase inhibitors and a-methyldopa." Lancet 1 (1963): 950-1. [PMID: 13975251]
172	van Rossum JM, Hurkmans JA "Reversal of the effect of a-Methyldopa by monamine oxidase inhibitors." J Pharm Pharmacol 15 (1963): 493-9. [PMID: 14059015]
173	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
174	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
175	Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y "QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine." Cardiology 84 (1994): 9-13. [PMID: 7511988]
176	Jain A, Jenkins MG "Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine." Cathet Cardiovasc Diagn 18 (1989): 255-7. [PMID: 2605630]
177	Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T "Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve." Cathet Cardiovasc Diagn 19 (1990): 229-36. [PMID: 2334953]
178	Nakayama M, Saito A, Kitazawa H, et.al "Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases." Intern Med 51 (2012): 351-6. [PMID: 22333368]
179	Nakayama M, Tanaka N, Sakoda K, et.al "Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease." Circ J 79 (2015): 530-6. [PMID: 25746536]
180	Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML "Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine." J Am Coll Cardiol 15 (1990): 275-8. [PMID: 2299067]
181	Vrolix M, Piessens J, De Geest H "Torsades de pointes after intracoronary papaverine." Eur Heart J 12 (1991): 273-6. [PMID: 2044564]
182	Product Information. Signifor (pasireotide). Novartis Pharmaceuticals, East Hanover, NJ.
183	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
184	Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
185	Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77. [PMID: 12544377]
186	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
187	Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate)." .
188	Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
189	FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms.".
190	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
191	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
192	Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996): 499-503. [PMID: 8799513]
193	Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
194	Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996): 161-7. [PMID: 8737135]
195	Lipsky BA, Dorr MB, Magner DJ, Talbot GH "Safety profile of sparfloxacin, a new fluoroquinolone antibiotic." Clin Ther 21 (1999): 148-59. [PMID: 10090432]
196	Product Information. Zagam (sparfloxacin). Rhone-Poulenc Rorer, Collegeville, PA.
197	Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72. [PMID: 9257738]
198	Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8. [PMID: 5794785]
199	Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL "Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans." Clin Pharmacol Ther 60 (1996): 543-53. [PMID: 8941027]
200	Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6. [PMID: 6145728]
201	Product Information. Mellaril (thioridazine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
202	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
203	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
204	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
205	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
206	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
207	Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
208	Product Information. Eligard (leuprolide). Sanofi Winthrop Pharmaceuticals, New York, NY.
209	Product Information. Firmagon (degarelix). Ferring Pharmaceuticals Inc, Tarrytown, NY.
210	Product Information. Lupron (leuprolide). TAP Pharmaceuticals Inc, Deerfield, IL.
211	Product Information. Plenaxis (abarelix). Praecis Pharmaceuticals Inc, Waltham, MA.
212	Product Information. Trelstar (triptorelin) Pharmacia and Upjohn, Kalamazoo, MI.
213	Product Information. Vantas (histrelin). Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
214	Product Information. Zoladex (goserelin). Zeneca Pharmaceuticals, Wilmington, DE.
215	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
216	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
217	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
218	Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308. [PMID: 28355969]
219	Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9. [PMID: 3305969]
220	Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7. [PMID: 26722167]
221	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
222	Product Information. Elspar (asparaginase). Merck & Co, Inc, West Point, PA.
223	Product Information. Erwinaze (asparaginase Erwinia chrysanthemi). EUSA Pharma, Newtown, PA.
224	Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.
225	Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671. [PMID: 29407583]
226	Product Information. Qelbree (viloxazine). Supernus Pharmaceuticals Inc, Rockville, MD.
227	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
228	Teodorovich N, Margolin E, Kogan Y, Paz O, Swissa M. Torsades de pointes after adenosine administration. J Electrocardiol. 2016;49(2):171-173. [PMID: 26850499]
229	Harrington GR, Froelich EG "Adenosine-induced torsades de pointes." Chest 103 (1993): 1299-1301. [PMID: 8131497]
230	Mallet ML "Proarrhythmic effects of adenosine: a review of the literature." Emerg Med J 21 (2004): 408-10. [PMID: 15208219]
231	Tachakra SS, Robinson S "Adenosine and cardiac arrhythmias." BMJ 305 (1992): 422. [PMID: 1392935]
232	Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992): 794-6. [PMID: 1539535]
233	Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
234	Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
235	Goodnick PJ, Jerry J, Parra F "Psychotropic drugs and the ECG: focus on the QTc interval." Expert Opin Pharmacother 3 (2002): 479-98. [PMID: 11996627]
236	Kane JM, Carson WH, Saha AR, et al. "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder." J Clin Psychiatry 63 (2002): 763-71. [PMID: 12363115]
237	Keck PE Jr, Marcus R, Tourkodimitris S, et al. "A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania." Am J Psychiatry 160 (2003): 1651-8. [PMID: 12944341]
238	Nelson S, Leung JG "Torsades de Pointes After Administration of Low-Dose Aripiprazole (February)." Ann Pharmacother (2013):. [PMID: 23362038]
239	Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study." J Clin Psychiatry 64 (2003): 1048-56. [PMID: 14628980]
240	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
241	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
242	Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8. [PMID: 9774942]
243	Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45. [PMID: 8234421]
244	Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14. [PMID: 9767726]
245	Abbas R, Hug BA, Leister C, Sonnichsen D "A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects." Int J Cancer 131 (2012): Epub. [PMID: 22065400]
246	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
247	Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
248	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
249	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
250	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
251	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
252	Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc, Palo Alto, CA.
253	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
254	Product Information. Exelon (rivastigmine) Novartis Pharmaceuticals, East Hanover, NJ.
255	Product Information. Razadyne (galantamine). Johnson and Johnson Medical Inc, Arlington, TX.
256	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
257	Product Information. Ellence (epirubicin) Pharmacia and Upjohn, Kalamazoo, MI.
258	Product Information. Halaven (eribulin). Eisai Inc, Teaneck, NJ.
259	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
260	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
261	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
262	Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7. [PMID: 11141163]
263	Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7. [PMID: 11549787]
264	Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6. [PMID: 16466123]
265	Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6. [PMID: 15687478]
266	Product Information. Floxin (ofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
267	Product Information. Levaquin (levofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
268	Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9. [PMID: 10569314]
269	Product Information. Lucemyra (lofexidine). US WorldMeds LLC, Louisville , KY.
270	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
271	US Food and Drug Administration "FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse.".
272	Product Information. Coartem (artemether-lumefantrine). Novartis Pharmaceuticals, East Hanover, NJ.
273	Canadian Pharmacists Association "e-CPS."
274	Product Information. Methotrexate (methotrexate). Lederle Laboratories, Wayne, NJ.
275	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
276	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
277	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
278	Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
279	Product Information. Betaseron (interferon beta-1b). Berlex, Richmond, CA.
280	Product Information. Plegridy (peginterferon beta-1a). Biogen Idec Inc, Cambridge, MA.
281	Product Information. Rebif (interferon beta-1a). Serono Laboratories Inc, Norwell, MA.
282	Product Information. Definity (perflutren). Lantheus Medical Imaging Inc, North Billerica, MA.
283	Product Information. Optison (perflutren). Mallinckrodt Medical Inc, St. Louis, MO.
284	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
285	Salik JM, Kurtin P "Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome." Am J Gastroenterol 80 (1985): 177-9. [PMID: 2983533]
286	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
287	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
288	Kim DH, Kweon TD, Nam SB, Han DW, Cho WY, Lee JS "Effects of target concentration infusion of propofol and tracheal intubation on QTc interval." Anaesthesia 63 (2008): 1061-4. [PMID: 18717665]
289	Kleinsasser A, Kuenszberg E, Loeckinger A, et.al "Sevoflurane, but not propofol, significantly prolongs the Q-T interval." Anesth Analg 90 (2000): 25-7. [PMID: 10624970]
290	Kleinsasser A, Loeckinger A, Lindner KH, Keller C, Boehler M, Puehringer F "Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol." Anaesthesia 56 (2001): 248-50. [PMID: 11251432]
291	Paventi S, Santevecchi A, Ranieri R "Effects of sevoflurane versus propofol on QT interval." Minerva Anestesiol 67 (2001): 637-40. [PMID: 11731753]
292	Scalese MJ, Herring HR, Rathburn RC, Skrepnek GH, Ripley TL "Propofol-associated QTc prolongation." Ther Adv Drug Saf 7 (2016): 68-78. [PMID: 27298717]
293	Staikou C, Stamelos M, Stavroulakis E "Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity." Br J Anaesth 112 (2014): 217-30. [PMID: 24305646]
294	Toyoda T, Terao Y, Oji M, Okada M, Fukusaki M, Sumikawa K "The interaction of antiemetic dose of droperidol with propofol on QT interval during anesthetic induction." J Anesth 27 (2013): 885-9. [PMID: 23660990]
295	Whyte SD, Booker PD, Buckley DG "The Effects of Propofol and Sevoflurane on the QT Interval and Transmural Dispersion of Repolarization in Children." Anesth Analg 100 (2005): 71-77. [PMID: 15616054]
296	Wutzler A, De Asmundis C, Matsuda H, et.al "Effects of propofol on ventricular repolarization and incidence of malignant arrhythmias in adults." J Electrocardiol 51 (2018): 170-4. [PMID: 29174097]
297	Product Information. Azilect (rasagiline). Teva Pharmaceuticals USA, North Wales, PA.
298	Smookler S, Barmudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant." Ann Emerg Med 11 (1982): 482-4. [PMID: 7114595]
299	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
300	Gilead Sciences, Inc "About Remdesivir.".
301	US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
302	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
303	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
304	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
305	Fenwick MJ, Muwanga CL "Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline." J Accid Emerg Med 17 (2000): 143-4. [PMID: 10718244]
306	Product Information. Xadago (safinamide). US WorldMeds LLC, Louisville , KY.
307	Thompson DS, Sweet RA, Marzula K, Peredes JC "Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient." J Clin Psychopharmacol 17 (1997): 322-3. [PMID: 9241014]
308	Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
309	Product Information. Sutent (sunitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
310	Demolis JL, Vacheron F, Cardus S, Funck-Brentano C "Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects." Clin Pharmacol Ther 73 (2003): 242-52. [PMID: 12621389]
311	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
312	European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) ".
313	Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
314	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
315	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
316	Product Information. Tabloid (thioguanine). Prasco Laboratories, Cincinnati, OH.
317	Product Information. Yondelis (trabectedin). Janssen Pharmaceuticals, Titusville, NJ.
318	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
319	Product Information. ProAmatine (midodrine). Roberts Pharmaceutical Corporation, Eatontown, NJ.
320	Multum Information Services, Inc. Expert Review Panel.
321	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
322	Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F "QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone." Pacing Clin Electrophysiol 28 (2005): 472-3. [PMID: 15869686]
323	Product Information. Flagyl (metronidazole). Searle, Skokie, IL.
324	Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN). Aptalis Pharma, Birmingham, AL.
325	Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908. [PMID: 12885102]
326	Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80.
327	Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7. [PMID: 3492908]
328	Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5. [PMID: 6970886]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence